Literature DB >> 22259150

Increased pouch sizes and resulting changes in the amounts of nicotine and tobacco-specific N-nitrosamines in single pouches of Camel Snus and Marlboro Snus.

Irina Stepanov1, Joni Jensen, Lois Biener, Robin L Bliss, Stephen S Hecht, Dorothy K Hatsukami.   

Abstract

INTRODUCTION: Initial analyses of the novel smokeless tobacco products Camel Snus and Marlboro Snus demonstrated that these products contain relatively low amounts of nicotine and the carcinogenic tobacco-specific nitrosamines N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), as compared with traditional smokeless products. It is unknown whether the modifications in packaging, flavors, and pouch sizes that occurred for both Camel Snus and Marlboro Snus since their first introduction to the market were accompanied by any changes in nicotine or nitrosamine levels.
METHODS: We examined the available data on nicotine and NNN and NNK levels in 60 samples of Camel Snus and 87 samples of Marlboro Snus that were analyzed in our laboratory between 2006 and 2010.
RESULTS: Due to the increase in pouch size, the amounts of total nicotine, unprotonated nicotine, and the sum of NNN and NNK present in the large Camel Snus pouches released in 2010 are 1.9-fold, 2.4-fold, and 3.3-fold higher, respectively, than in the original smaller pouches that entered the market in 2006. Total and unprotonated nicotine content in the current version of Marlboro Snus pouches are 2.1-fold and 1.9-fold higher, respectively, and the sum of NNN and NNK is 1.5-fold lower than in the original version.
CONCLUSIONS: We observed an increase in nicotine content in single portions of Camel Snus and Marlboro Snus, and an increase in tobacco-specific N-nitrosamine content in single portions of Camel Snus, due to the increases in pouch size that occurred between 2006 and 2010. This finding stresses the importance of tobacco product regulation and ingredient disclosures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22259150      PMCID: PMC3457708          DOI: 10.1093/ntr/ntr292

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  20 in total

1.  Oral tobacco products: preference and effects among smokers.

Authors:  Dorothy K Hatsukami; Joni Jensen; Amanda Anderson; Berry Broadbent; Sharon Allen; Yan Zhang; Herb Severson
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

2.  The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts.

Authors:  David T Levy; Elizabeth A Mumford; K Michael Cummings; Elizabeth A Gilpin; Gary Giovino; Andrew Hyland; David Sweanor; Kenneth E Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-12       Impact factor: 4.254

Review 3.  Oral manifestations of smokeless tobacco use.

Authors:  Robert O Greer
Journal:  Otolaryngol Clin North Am       Date:  2011-02       Impact factor: 3.346

4.  Tobacco-specific nitrosamines in new tobacco products.

Authors:  Irina Stepanov; Joni Jensen; Dorothy Hatsukami; Stephen S Hecht
Journal:  Nicotine Tob Res       Date:  2006-04       Impact factor: 4.244

5.  Prevalence of trial of snus products among adult smokers.

Authors:  Lois Biener; Kristen McCausland; Laurel Curry; Jennifer Cullen
Journal:  Am J Public Health       Date:  2011-02-17       Impact factor: 9.308

6.  Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.

Authors:  Michael Kotlyar; Louise A Hertsgaard; Bruce R Lindgren; Joni A Jensen; Steven G Carmella; Irina Stepanov; Sharon E Murphy; Stephen S Hecht; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-11-10       Impact factor: 4.254

Review 7.  Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke.

Authors:  S S Hecht; D Hoffmann
Journal:  Carcinogenesis       Date:  1988-06       Impact factor: 4.944

8.  Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers.

Authors:  Jian-Min Yuan; Woon-Puay Koh; Sharon E Murphy; Yunhua Fan; Renwei Wang; Steven G Carmella; Shaomei Han; Katie Wickham; Yu-Tang Gao; Mimi C Yu; Stephen S Hecht
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

Review 9.  Epidemiological evidence for the role of nitroso compounds in human cancer.

Authors:  S Preston-Martin; P Correa
Journal:  Cancer Surv       Date:  1989

10.  New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels.

Authors:  Irina Stepanov; Joni Jensen; Dorothy Hatsukami; Stephen S Hecht
Journal:  Nicotine Tob Res       Date:  2008-12       Impact factor: 4.244

View more
  11 in total

1.  Characteristics of "American Snus" and Swedish Snus Products for Sale in Massachusetts, USA.

Authors:  Andrew B Seidenberg; Olalekan A Ayo-Yusuf; Vaughan W Rees
Journal:  Nicotine Tob Res       Date:  2018-01-05       Impact factor: 4.244

2.  Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation.

Authors:  Andrew C Harris; Laura Tally; Clare E Schmidt; Peter Muelken; Irina Stepanov; Subhrakanti Saha; Rachel Isaksson Vogel; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2014-12-23       Impact factor: 4.492

3.  Naturalistic assessment of demand for cigarettes, snus, and nicotine gum.

Authors:  Jeffrey S Stein; A George Wilson; Mikhail N Koffarnus; Michael C Judd; Warren K Bickel
Journal:  Psychopharmacology (Berl)       Date:  2016-10-11       Impact factor: 4.530

4.  Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch.

Authors:  Irina Stepanov; Lois Biener; Katrina Yershova; Amy L Nyman; Robin Bliss; Mark Parascandola; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2014-03-06       Impact factor: 4.244

5.  Constituent Variations in Smokeless Tobacco Purchased in Mumbai, India.

Authors:  Irina Stepanov; Prakash C Gupta; Mark Parascandola; Katrina Yershova; Vipin Jain; Gauri Dhumal; Dorothy K Hatsukami
Journal:  Tob Regul Sci       Date:  2017-07

6.  Menthol decreases oral nicotine aversion in C57BL/6 mice through a TRPM8-dependent mechanism.

Authors:  Lu Fan; Shrilatha Balakrishna; Sairam V Jabba; Pamela E Bonner; Seth R Taylor; Marina R Picciotto; Sven-Eric Jordt
Journal:  Tob Control       Date:  2016-10-03       Impact factor: 7.552

7.  (S)-N'-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats.

Authors:  Silvia Balbo; Sandra James-Yi; Charles S Johnson; Michael G O'Sullivan; Irina Stepanov; Mingyao Wang; Dipankar Bandyopadhyay; Fekadu Kassie; Steven Carmella; Pramod Upadhyaya; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2013-05-13       Impact factor: 4.944

Review 8.  Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus.

Authors:  Micah L Berman; Warren K Bickel; Andrew C Harris; Mark G LeSage; Richard J O'Connor; Irina Stepanov; Peter G Shields; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2018-09-25       Impact factor: 4.244

9.  Brief, instructional smokeless tobacco use among cigarette smokers who do not intend to quit: a pilot randomized clinical trial.

Authors:  Jessica L Burris; Matthew J Carpenter; Amy E Wahlquist; K Michael Cummings; Kevin M Gray
Journal:  Nicotine Tob Res       Date:  2013-10-15       Impact factor: 4.244

10.  Associations between microbial communities and key chemical constituents in U.S. domestic moist snuff.

Authors:  Robert E Tyx; Angel J Rivera; Glen A Satten; Lisa M Keong; Peter Kuklenyik; Grace E Lee; Tameka S Lawler; Jacob B Kimbrell; Stephen B Stanfill; Liza Valentin-Blasini; Clifford H Watson
Journal:  PLoS One       Date:  2022-05-04       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.